Home  /  Resource Library  /  Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment Naive and Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment Naive and Relapsed or Refractory Chronic Lymphocytic Leukemia

Results of a phase II study investigating the combination of obinutuzumab, venetoclax and Ibrutinib for front line treatment of CLL.